Cancer Family
Hematopoietic and Lymphatic System Neoplasm
CI-CAN-00000022Explore in graph →
Non-malignant4,301 active trials98 approved drugs1,010 evidence items
- NCIt
- C35813
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000022Explore in graph →
Clinical trials
18,832 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00990717 | Safety Study Looking at the Use of a Natural Killer Cell Line Against Hematological Malignancies | completed | Phase 1 | 8 | University Health Network, TorontoOTHER | 1 | Jun 23, 2016 | clinicaltrials |
| NCT00698776 | Combination of Lenalidomide and Autologous Mature Dendritic Cells Pulsed With KRN7000 in Myeloma | completed | Phase 1 | 6 | Yale UniversityOTHER | 1 | Jun 21, 2016 | clinicaltrials |
| NCT01218477 | Dasatinib Combination Therapy With the Smoothened (SMO) Inhibitor BMS-833923 in Chronic Myeloid Leukemia (CML) | completed | Phase 1 / Phase 2 | 33 | Bristol-Myers SquibbINDUSTRY | 7 | Jun 17, 2016 | clinicaltrials |
| NCT01137747 | Carfilzomib in Patients With Relapsed Acute Myeloid or Acute Lymphoblastic Leukemia(AML ALL) | completed | Phase 1 | 18 | Washington University School of MedicineOTHER | 1 | Jun 14, 2016 | clinicaltrials |
| NCT00316030 | Study of Bexarotene in Patients With Acute Myeloid Leukemia | completed | Phase 1 | 54 | Abramson Cancer Center at Penn MedicineOTHER | 1 | Jun 8, 2016 | clinicaltrials |
| NCT01079936 | Lenalidomide and High-Dose Melphalan | completed | Phase 1 / Phase 2 | 61 | M.D. Anderson Cancer CenterOTHER | 1 | Jun 6, 2016 | clinicaltrials |
| NCT00036946 | VEGF Trap in Treating Patients With Relapsed or Refractory Solid Tumors or Non-Hodgkin's Lymphoma | completed | Phase 1 | — | Regeneron PharmaceuticalsINDUSTRY | 1 | Jun 3, 2016 | clinicaltrials |
| NCT00045266 | VEGF Trap in Treating Patients With Solid Tumors or Non-Hodgkin's Lymphoma | completed | Phase 1 | — | Regeneron PharmaceuticalsINDUSTRY | 1 | Jun 3, 2016 | clinicaltrials |
| NCT00410982 | Gemcitabine Plus Busulfan, Melphalan and Hematopoietic Cell Transplant for Advanced Lymphoid Malignancies | completed | Phase 1 | 145 | M.D. Anderson Cancer CenterOTHER | 1 | Jun 3, 2016 | clinicaltrials |
| NCT01912222 | Pharmacokinetic Study of Oral IXAZOMIB in Cancer Patients With Liver Dysfunction | completed | Phase 1 | 48 | Millennium Pharmaceuticals, Inc.INDUSTRY | 1 | Jun 2, 2016 | clinicaltrials |
| NCT01703364 | Fludarabine/Rituximab Combined With Escalating Doses of Lenalidomide in Untreated CLL | completed | Phase 1 / Phase 2 | 12 | Arbeitsgemeinschaft medikamentoese TumortherapieOTHER | 1 | May 26, 2016 | clinicaltrials |
| NCT01034553 | Aurora A Kinase Inhibitor MLN8237 and Bortezomib in Treating Patients With Relapsed or Refractory Multiple Myeloma | completed | Phase 1 / Phase 2 | 26 | Mayo ClinicOTHER | 1 | May 25, 2016 | clinicaltrials |
| NCT01088984 | Study of Bendamustine Hydrochloride for the Treatment of Pediatric Patients With Relapsed or Refractory Acute Leukemia | completed | Phase 1 / Phase 2 | 43 | Teva Branded Pharmaceutical Products R&D, Inc.INDUSTRY | 12 | May 23, 2016 | clinicaltrials |
| NCT01562990 | Phase Ib/II Study of the Efficacy and Safety of the R-CMC544/R-GEMOX Combination in Diffuse Lage B-cell Lymphoma at First or Second Relapse | completed | Phase 1 / Phase 2 | 11 | The Lymphoma Academic Research OrganisationOTHER | 2 | May 23, 2016 | clinicaltrials |
| NCT00330252 | Weekly Subcutaneous Alemtuzumab and Rituximab for Relapsed CLL | completed | Phase 1 | 29 | Dana-Farber Cancer InstituteOTHER | 1 | May 13, 2016 | clinicaltrials |
| NCT00546377 | Pentostatin, Cyclophosphamide, Rituximab, and Mitoxantrone in Treating Patients With Chronic Lymphocytic Leukemia or Other Low-Grade B-Cell Cancer | completed | Phase 1 / Phase 2 | 50 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | May 12, 2016 | clinicaltrials |
| NCT00299767 | Phase I Study of Sequential Cord Blood Transplants | completed | Phase 1 | 21 | Massachusetts General HospitalOTHER | 1 | May 11, 2016 | clinicaltrials |
| NCT01950364 | A Phase 1 Study in Patients With Relapsed or Refractory Hodgkin Lymphoma or Systemic Anaplastic Large Cell Lymphoma | completed | Phase 1 | 20 | Millennium Pharmaceuticals, Inc.INDUSTRY | 3 | May 11, 2016 | clinicaltrials |
| NCT00406978 | Melphalan, Prednisone, Thalidomide and Defibrotide in Relapsed Multiple Myeloma Patients(MPTD) | completed | Phase 1 / Phase 2 | 24 | Silvio AimeOTHER | 1 | May 10, 2016 | clinicaltrials |
| NCT01212380 | Study of Carfilzomib in Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL) or Prolymphocytic Leukemia (PLL) | completed | Phase 1 | 21 | Ohio State University Comprehensive Cancer CenterOTHER | 1 | May 9, 2016 | clinicaltrials |
| NCT00644124 | Aflibercept and Standard Chemotherapy (R-CHOP) in First Line of Non Hodgkin B-cell Lymphoma | completed | Phase 1 | 25 | SanofiINDUSTRY | 1 | May 6, 2016 | clinicaltrials |
| NCT01204164 | Phase 1 Study of TG02 Citrate in Patients With Advanced Hematological Malignancies(TG02-101) | completed | Phase 1 | 120 | Tragara Pharmaceuticals, Inc.INDUSTRY | 1 | May 6, 2016 | clinicaltrials |
| NCT01254890 | Sorafenib and 5-Azacitidine in Acute Leukemia + Myelodysplastic Syndrome | completed | Phase 1 / Phase 2 | 60 | M.D. Anderson Cancer CenterOTHER | 1 | May 6, 2016 | clinicaltrials |
| NCT00833833 | MTD, Safety, and Efficacy of Pomalidomide (CC-4047) Alone or With Low-dose Dexamethasone in Patients With Relapsed and Refractory Multiple Myeloma | completed | Phase 1 / Phase 2 | 259 | Celgene CorporationINDUSTRY | 2 | Apr 27, 2016 | clinicaltrials |
| NCT01680991 | A Study of Obinutuzumab in Chinese Participants With CD20+ Malignant Disease | completed | Phase 1 | 48 | Hoffmann-La RocheINDUSTRY | 1 | Apr 25, 2016 | clinicaltrials |
| NCT02337595 | Memory T-cell Infusion to Improve Immunity After TCR-alpha/Beta Depleted Hematopoietic Stem Cell Transplantation(45RA_NEG_DLI) | completed | Phase 1 / Phase 2 | 30 | Federal Research Institute of Pediatric Hematology, Oncology and ImmunologyOTHER | 1 | Apr 22, 2016 | clinicaltrials |
| NCT00428909 | Effect of Imatinib Mesylate and the Pharmacokinetics of Acetaminophen/Paracetamol in Patients With Newly Diagnosed, Previously Untreated Chronic Myeloid Leukemia in Chronic Phase (CML-CP) | completed | Phase 1 | 12 | Novartis PharmaceuticalsINDUSTRY | 1 | Apr 21, 2016 | clinicaltrials |
| NCT01744626 | Safety Study of CC-292 and Rituximab in Subjects With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma | completed | Phase 1 | 40 | Celgene CorporationINDUSTRY | 2 | Apr 19, 2016 | clinicaltrials |
| NCT01075425 | Belinostat and Bortezomib in Treating Patients With Relapsed or Refractory Acute Leukemia or Myelodysplastic Syndrome | completed | Phase 1 | 41 | Virginia Commonwealth UniversityOTHER | 1 | Apr 15, 2016 | clinicaltrials |
| NCT01804335 | CD5789 in Early Cutaneous T-Cell Lymphoma (CTCL) | completed | Phase 1 | 11 | M.D. Anderson Cancer CenterOTHER | 1 | Apr 13, 2016 | clinicaltrials |
| NCT01394354 | Vorinostat in Combination With Bortezomib, Doxorubicin and Dexamethasone (VBDD) in Patients With Refractory or Relapsed Multiple Myeloma (MM)(VBDD) | completed | Phase 1 / Phase 2 | 34 | University Hospital FreiburgOTHER | 1 | Apr 6, 2016 | clinicaltrials |
| NCT00552396 | An Open-label, Dose-escalation Safety and Tolerability Trial Assessing Anti-KIR (1-7F9) in Subjects With Multiple Myeloma | completed | Phase 1 | 32 | Innate PharmaINDUSTRY | 1 | Mar 31, 2016 | clinicaltrials |
| NCT02723071 | A Study of Ocrelizumab in Participants With Follicular Non-Hodgkin's Lymphoma (NHL) | completed | Phase 1 / Phase 2 | 48 | Hoffmann-La RocheINDUSTRY | 6 | Mar 30, 2016 | clinicaltrials |
| NCT00529360 | Allogeneic Stem Cell Transplant With Clofarabine, Ara-C and TBI for AML and ALL | completed | Phase 1 / Phase 2 | 32 | New York Medical CollegeOTHER | 1 | Mar 24, 2016 | clinicaltrials |
| NCT01433731 | Safety, Pharmacodynamics (PD), Pharmacokinetics (PK) Study of SHP141 in 1A, 1B, or 2A Cutaneous T-Cell Lymphoma (CTCL) | completed | Phase 1 | 18 | TetraLogic PharmaceuticalsINDUSTRY | 1 | Mar 24, 2016 | clinicaltrials |
| NCT01681537 | Lenalidomide Plus Chemotherapy for AML | completed | Phase 1 | 36 | Massachusetts General HospitalOTHER | 1 | Mar 17, 2016 | clinicaltrials |
| NCT01359657 | Anti-CXCR4 (BMS-936564) Alone and in Combination With Lenalidomide/Dexamethasone or Bortezomib/Dexamethasone in Relapsed/Refractory Multiple Myeloma | completed | Phase 1 | 46 | Bristol-Myers SquibbINDUSTRY | 1 | Mar 16, 2016 | clinicaltrials |
| NCT01567475 | The Combination of Rad001 and Rituximab In Patients With Non-hodgkin's Lymphomas((RAD001-R)) | completed | Phase 1 | 21 | The Lymphoma Academic Research OrganisationOTHER | 1 | Mar 15, 2016 | clinicaltrials |
| NCT01398462 | Phase I Clinical Study of CWP232291 in Acute Myeloid Leukemia Patients | completed | Phase 1 | 69 | JW PharmaceuticalINDUSTRY | 2 | Mar 8, 2016 | clinicaltrials |
| NCT00398138 | Vaccine Therapy and GM-CSF in Treating Patients With Acute Myeloid Leukemia, Myelodysplastic Syndromes, Non-Small Cell Lung Cancer, or Mesothelioma | completed | Phase 1 | 22 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Mar 2, 2016 | clinicaltrials |
| NCT00850382 | Dasatinib (Sprycel™) in Patients With Newly Diagnosed Core Binding Factor (CBF) Acute Myeloid Leukemia (AML) | completed | Phase 1 / Phase 2 | 89 | University of UlmOTHER | 2 | Mar 1, 2016 | clinicaltrials |
| NCT01352338 | Revlimid, Endoxan, Prednison Evaluation After Prior Revlimid Treatment (REPEAT)(REPEAT) | completed | Phase 1 / Phase 2 | 82 | UMC UtrechtOTHER | 1 | Feb 26, 2016 | clinicaltrials |
| NCT01413568 | Safety and Efficacy of POL6326 for Mobilization/Transplant of Sibling Donor in Patients With Hematologic Malignancies | completed | Phase 1 / Phase 2 | 38 | Polyphor Ltd.INDUSTRY | 1 | Feb 26, 2016 | clinicaltrials |
| NCT01690507 | Decitabine Combining Modified CAG Followed by HLA Haploidentical Peripheral Blood Mononuclear Cells Infusion for Elderly Patients With Acute Myeloid Leukemia(AML） | completed | Phase 1 / Phase 2 | 29 | Chinese PLA General HospitalOTHER | 1 | Feb 25, 2016 | clinicaltrials |
| NCT02040506 | A Phase I Study of IGN523 in Subjects With Relapsed or Refractory AML | completed | Phase 1 | 19 | Igenica Biotherapeutics, Inc.INDUSTRY | 1 | Feb 23, 2016 | clinicaltrials |
| NCT00761384 | High Dose, Absorbed Dose Adjusted 90Y-ibritumomab With Peripheral Blood Stem Cells (PBSC) Support in B-cell Lymphoma(HITT) | completed | Phase 1 / Phase 2 | 7 | Lund University HospitalOTHER | 1 | Feb 19, 2016 | clinicaltrials |
| NCT00986804 | Decitabine Maintenance for Acute Myelogenous Leukemia (AML) and Myelodysplastic Syndrome (MDS) Post Transplant(AML MDS) | completed | Phase 1 | 24 | Washington University School of MedicineOTHER | 1 | Feb 15, 2016 | clinicaltrials |
| NCT00892190 | Study of Dasatinib and All-Trans Retinoic Acid for Relapsed/Refractory and/or Elderly Patients With Acute Myelogenous Leukemia (AML) or Myelodysplastic Syndrome | completed | Phase 1 | 9 | University of PittsburghOTHER | 1 | Feb 10, 2016 | clinicaltrials |
| NCT00438880 | Agatolimod Sodium, Rituximab, and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Recurrent or Refractory Non-Hodgkin Lymphoma | completed | Phase 1 / Phase 2 | 38 | Mayo ClinicOTHER | 1 | Feb 4, 2016 | clinicaltrials |
Data updated 24 days agoSource updated Jun 23, 2016source: clinicaltrials